Index

Page numbers in italics denote figures, those in bold denote tables.

acamprosate 23
acetaminophen (APAP) 34, 35, 42, 67, 73
dosage 45
opioid combinations 27, 31, 39
pain relief 44
precautions and contraindications 36
acetylsalicylic acid (aspirin) 34
precautions and contraindications 36
active listening 160
acupressure 64
acupuncture 64
acute inflammatory pain 2, 31, 32–33
Adderall® see dextroamphetamine
addiction
culture 9
definition 2, 11–12, 178
medical model 12
neurobiology 179–80
in practitioners 177–90, 204–5
conspiracy of silence 183–4
epidemiology 180
evaluation and assessment 185
family and staff involvement 186–7
identification 183
intervention 184–5
monitoring 187
peer assistance/dental well-being committee programs 187–9
relapse 187
risk factors 180–2
substance of choice 182–3
treatment 186
recognition of 178–9, 179
stigma of 180
addiction support programs 188
aerosols 95–6
age, and SUD 13–14
alcohol abuse 6, 89, 97–8, 201
and benzodiazepines 196
blood alcohol concentration 16, 16
dental considerations 99
and liver disease 198, 202
in practitioners 182–3
signs and symptoms 6, 15–16, 16
treatment 22–3
withdrawal symptoms 16, 98
Alcohol Use Disorders Identification Test (AUDIT) questionnaire 165
Alcoholics Anonymous 21–2, 21
alfentanil 67
alpha agonists 67, 74–5
alprazolam 70, 108
ambivalence 12
American Psychiatric Association 4
amobarbital 108
amphetamine 107
anabolic steroids 111, 111
analgiesia see pain management anesthesia 62–4, 63
balanced 76
general 62
inhalation anesthetics 75, 75
local see local anesthetics stages of 63
Antabuse® see disulfiram
anticholinergics 67
anticonvulsants 110
antihistamines 67, 74, 74, 111
antipsychotics 109
anxiolyis 61–2
see also sedation
APAP see acetaminophen
aspirin see acetylsalicylic acid
Ativan® see lorazepam
atropine 67
AUDIT see Alcohol Use Disorders Identification Test
balanced anesthesia 76
barbiturates 67, 108–9
dental considerations 108
see also individual drugs
“bath salts” see cathinones, synthetic
behavioral coping 120
benzodiazepines 107–8, 108
drug addiction 16–17
treatment 23
withdrawal 17
adverse effects 70
and alcohol abuse 196
dental considerations 108
reversal 71
dedation 67, 69–71, 70
biofeedback 64
blood alcohol concentration 16, 16
brand switching 125
Buprenex® see buprenorphine
buprenorphine 25, 26, 39, 50–1, 72, 106
acute dental pain in OMT patients 54–5
buprenorphine/naloxone 26, 39, 41
bupropion 131–2, 134–7
butalbital 109
butorphanol 26
CAGE questionnaire 143, 164
Campral® see acamprosate
cannabinoids, synthetic 100
cannabis abuse 19, 78, 89, 98–9, 201
dental considerations 100
treatment 25
caries
in heroin users 94
and smoking 121
carisoprodol 110
cathinones, synthetic 91
dental considerations 92
cleocoxib 34, 35
Centers for Disease Control 1
central nervous system depressants 97–8, 107–8, 107
see also individual drugs
Chantix see varenicline
chewing tobacco 121
chloral hydrate 67
chlordiazepoxide 70
cigarette smoking
incidence 120
second-hand smoke 122
see also tobacco; tobacco cessation
clonazepam 107
clonidine 67, 73
tobacco cessation 133
cocaine abuse 78, 86, 87, 90, 199
dental considerations 91
codeine 26, 39, 105–6
codene/APAP 26, 39
cognitive behavioral therapy 21
cognitive coping 119–20
Concerta® see methylphenidate
consent or mandated programs 188
contingency management 21
Controlled Substance Act (1970) 103, 152, 169
controlled substances 101, 169–76
common violations 170–3
disposal 153–4, 171
documentation 171–3, 172, 174
Drug Enforcement Administration inspections 173, 175
due diligence 170, 175–6, 191
federal statues and regulations 169
record keeping 170, 171
prescriber controlled-substance reports 153
safe prescribing 202–4
storage 171
universal precautions 154–7
coping strategies
behavioral coping 120
cognitive coping 119–20
corticosteroids 42–3
counseling 159–67
COX-2 inhibitors 34–5, 34
CRAFFT 165, 165
cross-addiction 12
cross-tolerance 48
cyclobenzaprine 110
depth sedation 62, 76
Demerol® see meperidine
denial 178
dental practitioners see practitioners
dental well-being programs 187–9
designer drugs 19–20
dexmedetomidine 67, 74
dextroamphetamine 18, 107
dextromethorphan 111
Diagnostic and Statistical Manual of Mental Disorders-IV see DSM-IV-TR
diazepam 67, 70, 107–8
diclofenac 34
diclofenac/APAP 43
difunisal 34
Dilantin® see phenytoin
diphenhydramine 67
dosage 74
dispensing 170
disulfiram 22
diversion behaviors 2–3, 6–7, 141–2
patients 144–7
in office 144–6
outside office 147
privacy of 152
practitioner/office personnel 147–8
prevention practices 146–7, 156–7
recognition of 192–4, 193
red flags 146
reporting of 150, 152, 194
doctor/dentist shopping 142, 145, 162
patient privacy 152
documentation
controlled substances 171–3, 172, 174
motivational interviewing 165–6
see also record keeping
Dolophine® see methadone
dopamine beta-hydroxylase 23
Dormicum® see midazolam
drug diversion see diversion behaviors
Drug Enforcement Administration inspections 173, 175
drug misuse 2–3, 83
drug-seeking 160
diversion behaviors see diversion behaviors
doctor/dentist shopping 142, 145, 162
DSM-IV-TR 4
due diligence 170, 175–6, 191
ecstasy 20
electronic cigarettes 133
electronic dental anesthesia 64
ethanol see alcohol abuse
etodolac 34
family history 181
fentanyl 26–7, 39, 67, 104
Flexeril see cyclobenzaprine
Flumazenil® 71
Food, Drug, and Cosmetic Act 133
FRAMES mnemonic 20
Index

gabapentin 110

gamma-hydroxybutyrate 98
gender, and SUD 13–14
general anesthesia 62
Geodon® see ziprasidone
glucocorticoids 42
glue-sniffer’s rash 95
glycopyrrolate 67
Guedel, Arthur 62

Halcion® see triazolam
hallucinogen abuse 19–20, 91–4
dental considerations 93
treatment 25
see also individual drugs
hashish 98–9
Health Insurance Portability and Accountability Act (1996) 149, 175
heroin abuse 88, 94–5, 94, 95, 200
dental considerations 96
histamines 2
hookahs 121
huffing see inhalant abuse
hydrocodone 27, 102–4, 104
drug interactions 103
hydrocodone/APAP 27, 31, 39, 43
dosage 45
hydrocodone/ibuprofen 39
hydromorphone 39, 104
hydroxyzine 67
dosage 74
hyperalgesia 48, 52, 57
hypnosis 64
hypnotics 67

iatrosedation 64
ibuprofen 34, 34
dosage 45
opioid combinations 39
pain relief 44
ibuprofen/APAP 44
illicit drug use 1
impairment in dental practitioners 178, 204–5
potential causes 179
see also addiction
income-driven culture 8

inhalant abuse 19–20, 95–7
dental considerations 97
treatment 25
see also specific types
inhalation anesthetics 75, 75
interviews see motivational interviewing
intramuscular injection 67
intranasal administration 66

ketamine 67, 72–3, 73, 110–11
adverse effects 73
ketoprofen 34
ketoprofen/APAP 43
ketorolac 34, 67, 73
khat 90
Klonopin® see clonazepam

liver disease, and alcohol abuse 198, 202
local anesthetics 75–6
adverse reactions 76
long-acting 41–2
lorazepam 67, 70, 108
lovorphanol 27
LSD 20, 87, 92, 199
Luminal® see phenobarbital
lysergic acid diethylamide see LSD

marijuana see cannabis abuse
MDMA 88, 92–3, 200
systemic effects 93
medical model of substance abuse 12
medication misuse 1, 5–6
medication-assisted therapy 12
medlofenamate 34
meperidine 27, 39, 67, 71
mescaline 20, 92
methadone 24, 39, 41, 50–1, 72, 104–5
acute dental pain in OMT patients 54–5
methamphetamine abuse 86, 87, 199
dental considerations 90
methohexital 67
3,4-methylenedioxyamphetamine see MDMA
methylenedioxyamphetamine 18, 107
Michigan Alcohol Screening Test 164
midazolam 67, 69–70, 70
minimal sedation 61–2
moderate sedation 62, 76
morphine 27, 67, 71, 104
motivational interviewing 20, 159–67
definition 160
documentation 165–6
flag behaviors 162
preinterview considerations 160–1
questionnaires see questionnaires
questions 161–2, 163–4
screening tools 164–5
techniques 162–3
active listening 160
mucosal atomization device (MAD™) 66
muscle relaxants 75, 110

nalbuphine 39
naloxone 39
naltrexone 23, 25, 39, 51
and dental analgesia 56–7
depot 23, 25
Narcotic Drug Act (1932) 152
National Health and Aging Trends Study 1
National Institute of Drug Abuse Drug Use
Screening Tool 143–4
National Survey on Drug Use and Health 1
neuromuscular blockers 75
Neurontin® see gabapentin
neuropathic pain 2
NicoDerm CQ 134–7
Nicorette 134–7
Nicorette Lozenge 134–7
nicotine addiction 19, 26, 126–7
withdrawal 127
see also tobacco; tobacco cessation
nicotine fading 125
nicotine replacement therapy 120, 126, 127–38,
134–7
efficacy 130
formulations 131, 134–7
gum 128–9
inhaler 129–30
lozenges 129
nasal spray 130
patches 128, 128
product selection 130

nicotine toxicity 128
Nicotrol Inhaler 134–7
Nicotrol NS 134–7
nitrites 96–7
nitrous oxide abuse 68–9, 96
in practitioners 183
non-steroidal anti-inflammatory drugs see NSAIDs
noncontrolled substances see over-the-counter
drugs
nonopioid analgesics 33–8, 34
COX-2 inhibitors 34–5, 34
drug interactions 36–7, 37
precautions and contraindications 35–6, 37
see also individual drugs
nortriptyline 133
NSAIDs 7, 42
acute dental pain 51
drug interactions 37–8
ACE inhibitors, diuretics and beta-blockers 37
alcohol 37
anticoagulant therapy 37
lithium 38
methotrexate 38
precautions and contraindications 36
see also individual drugs
OARS mnemonic 20
office staff, drug diversion behaviors 147–8
olanzapine 109
OMT see opioid maintenance therapy
opiates see opioids
opioids 3, 26–8, 38–41, 39, 83
adverse effects 40–1, 40, 72
for chronic pain 57
dependence see opioid dependence
drug interactions 40–1, 40
sedation 71–2
opioid agonists 67
opioid antagonists 39
opioid dependence 3, 7, 17–18, 83, 88, 94–5, 94,
95, 101–2, 200
adjuvant therapy 73
adverse effects 102
opioid dependence (Continued)
dental analgesia 55–6
dental considerations 103
intoxication 18
management see opioid maintenance therapy
therapy goals 47, 49–50
withdrawal 18, 72
opioid maintenance therapy (OMT) 23–5, 24, 47, 48, 49–51
dental analgesia 51–5, 196–7
see also individual drugs
opioid-based maintenance programs 72
opium 88, 94–5, 94, 95, 200
oral cancer 122
over-the-counter drugs 111–12, 176
see also individual drugs
overprescribing 5
oxycodone 28, 39, 102–4, 104, 202
drug interactions 103
oxycodone/APAP 27, 28, 39, 42, 44, 202
oxycodone/ibuprofen 39
oxymorphone 104

pain 31
acute 2, 31, 32–3, 32, 33
chronic 2, 31
neuropathic 32
nociceptive 2, 31, 32
pain fibers 33
pain management 1, 7–8, 31–46
active opioid addicts 55–6
acute dental pain 51
acute “on” chronic 198
adjunctive drugs 41–3
corticosteroids 42–3
long-acting local anesthetics 41–2
preemptive analgesics 42
ethical issues 194–6
guidelines 43–5, 44, 45
nonopioid 33–8, 34
OMT patients 51–5, 196–7
opioids see opioids
patients on naltrexone therapy 56–7
patients receiving opioids for chronic pain 57
pain perception 49, 84–5
paints, sniffing 88, 95–6, 200
paracetamol see acetaminophen

patient privacy 152
patient-centered approach 160
peer assistance programs 187–9
pentazocine 28, 39
pentazocine/APAP 39
pentazocine/naloxone 39
Percocet® see oxycodone/APAP
perpetual inventory form 174
phencyclidine 92
phenobarbital 108–9
phenytoin 110
physical status classification 65
polypharmacy 1
“poppers” see nitrites
practitioners
addiction in 177–90, 204–5
conspiracy of silence 183–4
epidemiology 180
evaluation and assessment 185
family and staff involvement 186–7
identification 183
intervention 184–5
monitoring 187
peer assistance/dental well-being committee programs 187–9
relapse 187
risk factors 180–2
substance of choice 182–3
treatment 186
definition 170
diversion behaviors 147–8
scope of practice 170–1
Precedex® see dexmedetomidine
preemptive analgesia 42
pregabalin 73
preoperative evaluation 64
prescriber controlled-substance reports 153
prescriber-patient mismatch 3, 192
prescriptions 169–70
prescription drug monitoring programs 148–50, 159, 160, 193, 193
access to 153
case study 150, 151
prescription drugs 100–12
controlled substances see controlled substances
misuse 1, 5–6, 84
overdose 1
overprescribing 5
safe prescribing see safe prescribing
seeker behavior 144–7
see also individual drugs
prevention of drug diversion 146–7, 156–7
promethazine 67
propofol 67, 73
propoxyphene 40
prostaglandins 2
pseudo-addiction 48
pseudoephedrine 18, 112
psilocybin 92
psychotherapeutic drugs 1
psychotherapy 12

questionnaires see screening tools
quetiapine 109

readily retrievable records 170, 171
ready-access list 9
record keeping
controlled substances 153, 170, 171
noncontrolled substances 176
relapse 187, 191
reporting to law enforcement 150, 152, 194
patient privacy 152
ReVia® see naltrexone
Reye’s syndrome 36
Ritalin® see methylphenidate
Romazicon® 71

safe prescribing 191–206
controlled substances 202–4
recognition of diversion behaviors 192–4, 193
reporting to law enforcement 150, 152, 194
Salvia divinorum 94
SBIRT see Screening, Brief Intervention, Referral for Treatment
scope of practice 170–1
scopolamine 67
Screening, Brief Intervention, Referral for Treatment (SBIRT) 142–3, 164–5
screening tools 142–4, 152–3, 164–5, 165
AUDIT questionnaire 165
CAGE questionnaire 143, 164
CRAFFT 165, 165
Michigan Alcohol Screening Test 164
National Institute of Drug Abuse Drug Use Screening Tool 143–4
SBIRT 152–3, 164–5
sedation 61–82
available drugs 67
deep sedation 62
emergencies 77
iatroscopy 64
ideal 66
minimal sedation (anxiolysis) 61–2
moderate sedation 62
monitoring and documentation 76
physical status classification 65
preoperative evaluation 64
rescue 64
routes of administration 66
special considerations 77–8
spectrum of 63
SUD patients 68–76
benzodiazepines 69–71, 70
nitrous oxide-oxygen 68–9
self-report programs 188
Seroquel® see quetiapine
sharing culture 8
snuff 121
sodium thiopental 67
solvents 88, 95–6, 200
Soma® see carisoprodol
spit products 120, 121
interventions 124–5
oral substitutes 125
stigma of addiction 180
stimulant abuse 18–19, 86, 90–1, 107
intoxication 18
tooth pain 197–8
treatment 25
withdrawal 19
see also individual drugs
stress, and addiction 181–2
subcutaneous injection 67
Suboxone® see buprenorphine; buprenorphine/naloxone
substance abuse 3, 84
culture 7–8
medical model 12
substance dependence 3–4
Index

substance P 2
substance use disorder (SUD) 1–2, 4–5, 11–29
  age-related 13–14
  brain pathways 14–15, 15
  counseling patients 159–67
  cultures of 8–9
  definitions 11–13, 84
  detection/deterrence 141–58
  epidemiology 13–14
  gender-related 13–14
  pathophysiology 14–15, 15
  in practitioners 177–90
  risk factors 180–2
    family history 181
    stress 181–2
  screening tools 142–4, 152–3, 164–5, 165
    AUDIT questionnaire 165
    CAGE questionnaire 143, 164
    CRAFFT 165
    National Institute of Drug Abuse Drug Use Screening Tool 143–4
    SBIRT 142–3, 164–5
  symptoms 4, 15–20, 84, 85, 85
  treatment 14, 20–8
    behavioral modifications and counseling 20–2, 22
    medications 22, 22
    see also specific disorders
Subutex® see buprenorphine
SUD see substance abuse disorder

tapentadol 28, 39

tobacco
  forms of 121
  oral effects 121–2
    see also nicotine addiction
  tobacco cessation 119–40
  ask-advise-refer 122–3
  blending 125
  brand switching 125
  creating a plan 123–4
  electronic cigarettes 133
medication management 126
motivate-educate-refer 123
nicotine fading 125
oral substitutes 125
pharmacotherapy
  bupropion 131–2
  clonidine 133
  nicotine replacement therapy see nicotine replacement therapy
  nortriptyline 133
  varenicline 132–3
  resources 123
  social support 125–6
  spit products 124–5
tolerance 13, 84
tramadol 28, 40, 106
tramadol/APAP 28, 39
transtheoretical model of change 13, 13
triazolam 67, 70
universal precautions for controlled substances 154–7

Valium® see diazepam
varenicline 132–3, 134–7
Versed® see midazolam
Vicodin® see hydrocodone/APAP
visual analog pain scale (VAPS) 49, 84–5
Vivitrol® see naltrexone
withdrawal 13
  alcohol 16
  benzodiazepines 17
  cannabis 19
  nicotine 19
  opioids 18
  stimulants 19

Xanax® see alprazolam
ziprasidone 109
Zubsolv® see buprenorphine
Zyban see bupropion
Zyprexa® see olanzapine